Johnson & Johnson Purchase Proteologix for $850 Million

By investing $850 million in Proteologix, Johnson & Johnson will acquire a nascent portfolio of bispecific immunology medications, which includes a phase 1-ready product that focuses on TSLP.

Included in J&J’s acquisition is PX130, an antibody that targets IL-13 and IL-22 and is being developed in preliminary research for AD. The business contends that increasing inhibiting capabilities might maximise effectiveness and raise rates of remission because both AD and asthma are diverse illnesses.

Global immunology therapeutic head for J&J explained: “We see an opportunity for best-in-disease efficacy for both PX128 and PX130 as each bispecific antibody targets two different combinations of disease-driving pathways that are mediating the skin inflammation in heterogeneous subpopulations of AD patients.”